Cytokines as Potential Novel Therapeutic Targets in Severe Inflammatory Cardiomyopathy
Suwalski, P.; Golpour, A.; Weiner, J.; Musigk, N.; Balzer, F.; Giesa, N.; Amr, A.; Trebing, J.; Sedaghat, F.; Meder, B.; Beule, D.; Landmesser, U.; Heidecker, B.
Show abstract
BackgroundDespite currently available state-of-the art therapies, a substantial proportion of patients with inflammatory cardiomyopathy progresses to advanced heart failure. There is an urgent need for novel therapies to improve outcomes. We hypothesized that elevated cyto-kine levels in inflammatory cardiomyopathy may lead to cardiac injury and that specific cyto-kines are associated with severely decreased left ventricular function consequently, thereby suggesting their potential as therapeutic targets. Methods and ResultsBlood samples collected from 529 patients at 2 registries were inves-tigated. First, in a derivation cohort of inflammatory cardiomyopathy from our medical center (n=63), we discovered cytokines that correlate inversely with severely decreased left ventricu-lar ejection fraction (LVEF). We confirmed reproducibility of our results in an independent cohort from a national registry (n=425) and to some degree generalizability in a small cohort of idiopathic dilated cardiomyopathy (IDCM, n=41). In total, we identified 82 cytokines asso-ciated with severely decreased LVEF (FDR < 0.05); a small portion had been previously pro-posed as therapeutic targets, while others emerged as novel discoveries. Finally, real-world data from electronic medical records further indicated the potential of inhibitors targeting cy-tokines of interest to confer a cardioprotective effect. ConclusionsWe identified 82 cytokines associated with severe inflammatory cardiomyopa-thy. Our data were highly significant, reproducible, and generalizable to IDCM. The fact that some of the cytokines had been suggested as potential targets in prior literature supports va-lidity and plausibility of our data. Given that inhibition of cytokines is technically feasible, the identified proteins are compelling potential novel therapeutic targets. Trial registration number: ClinicalTrials.gov Identifier: NCT04265040, NCT02187263 VISUAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=118 SRC="FIGDIR/small/23293253v1_ufig1.gif" ALT="Figure 1"> View larger version (54K): org.highwire.dtl.DTLVardef@1dbe69aorg.highwire.dtl.DTLVardef@c0cforg.highwire.dtl.DTLVardef@1725609org.highwire.dtl.DTLVardef@16e823b_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 4 journals account for 50% of the predicted probability mass.